Safety and Preliminary Efficacy of Ramucirumab in Combination with FOLFOX4 in Patients with Advanced Hepatocellular Carcinoma: A Nonrandomized, Open‐Label, Phase Ib Study

LESSONS LEARNED: The combination of ramucirumab (8 mg/kg intravenous, day 1 every 2 weeks) and FOLFOX4 as first‐line treatment in patients with advanced hepatocellular carcinoma (HCC) was not sufficiently tolerated. Preliminary efficacy data suggest that the combination may provide clinical benefit...

Descripción completa

Detalles Bibliográficos
Autores principales: Lin, Chia‐Chi, Yang, Tsai‐Sheng, Yen, Chia‐Jui, Cheng, Rebecca, Liu, Junjun, Hsu, Chiun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2020
Materias:
Clinical Trial Results
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8108062/
https://www.ncbi.nlm.nih.gov/pubmed/33017497
http://dx.doi.org/10.1002/onco.13550

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8108062/
https://www.ncbi.nlm.nih.gov/pubmed/33017497
http://dx.doi.org/10.1002/onco.13550

Ejemplares similares